Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PDS 0101

Drug Profile

PDS 0101

Alternative Names: PDS 101; PDS-0101; PDS-0101C; PDS0101A; PDS0101B; Versamune; Versamune-HPV

Latest Information Update: 15 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator PDS Biotechnology Corporation
  • Developer Merck & Co; National Cancer Institute (USA); PDS Biotechnology Corporation
  • Class Cancer vaccines; Immunotherapies; Papillomavirus vaccines; Peptide vaccines
  • Mechanism of Action CD8 positive T lymphocyte stimulants; Immunostimulants; Interferon gamma stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Anal intraepithelial neoplasia; Cancer; Cervical cancer; Cervical intraepithelial neoplasia; Head and neck cancer

Most Recent Events

  • 15 Nov 2019 PDS Biotechnology withdraws a phase II trial prior to enrolment in Cervical dysplasia (Monotherapy) as the company has decided to prioritise their platform's application in combination therapies to address advanced cancers
  • 03 Oct 2019 PDS Biotechnology enters into a clinical trial collaboration agreement with Merck & Co for Head and neck cancer (Combination therapy, Metastatic disease, Recurrent, First line therapy)
  • 03 Oct 2019 PDS Biotechnology Corporation and Merck & Co plans a phase II trial for Head and neck cancer (Combination therapy, Recurrent, Metastatic disease, First-line therapy) in the first quarter of 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top